Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study - Concepedia

Concepedia

Publication | Open Access

Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

DOI Full Paper Access

101

Citations

17

References

2020

Year

Nicholas J. Vogelzang, Mark R. Olsen, Joshua J. McFarlane, Edward Arrowsmith, Todd M. Bauer, Rohit Jain, Bradley G. Somer, Elaine T. Lam, Mark D. Kochenderfer, Ana M. Molina,

Clinical Genitourinary Cancer

Abstract

Safety of flat-dose nivolumab 240 mg Q2W was consistent with previous results. Clinically meaningful efficacy was observed with responses in several histologies, supporting nivolumab as a treatment option for patients with advanced nccRCC, a patient population with high unmet need.

References

	Year	Citations

Page 1